Skip to Content

Generic Nexavar Availability

Last updated on Aug 11, 2021.

Nexavar is a brand name of sorafenib, approved by the FDA in the following formulation(s):

NEXAVAR (sorafenib tosylate - tablet;oral)

  • Manufacturer: BAYER HLTHCARE
    Approval date: December 20, 2005
    Strength(s): EQ 200MG BASE [RLD]

Has a generic version of Nexavar been approved?

No. There is currently no therapeutically equivalent version of Nexavar available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexavar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Aryl ureas with angiogenesis inhibiting activity
    Patent 8,618,141
    Issued: December 31, 2013
    Assignee(s): Bayer Healthcare LLC

    This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

    Patent expiration dates:

    • February 11, 2023
      ✓ 
      Patent use: TREATMENT OF ADVANCED RENAL CELL CARCINOMA
  • Thermodynamically stable form of a tosylate salt
    Patent 8,877,933
    Issued: November 4, 2014
    Assignee(s): Bayer Intellectual Property GmbH

    The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.

    Patent expiration dates:

    • December 24, 2027
      ✓ 
      Patent use: TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical composition for the treatment of cancer
    Patent 9,737,488
    Issued: August 22, 2017
    Assignee(s): Bayer HealthCare LLC

    The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.

    Patent expiration dates:

    • September 10, 2028
      ✓ 
      Patent use: TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
      ✓ 
      Drug product
    • September 10, 2028
      ✓ 
      Patent use: TREATMENT OF ADVANCED RENAL CELL CARCINOMA
      ✓ 
      Drug product
    • September 10, 2028
      ✓ 
      Patent use: TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.